Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

20 Dec 2021

Abstract excerpt

Despite recent discoveries and therapeutic advances in aggressive myeloid neoplasms, there remains a pressing need for improved therapies. For instance, in acute myeloid leukemia (AML), while most patients achieve a complete remission with conventional chemotherapy or the combination of a hypomethylating agent and venetoclax, de novo or acquired drug resistance often presents an insurmountable challenge,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34945003
DOI: 10.3390/cancers13246385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged SwordPMID 34945003Read ↗

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategiesSemantic proximity Read ↗

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndromeSemantic proximity Read ↗

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.Semantic proximity Read ↗

Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case seriesSemantic proximity Read ↗

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsSemantic proximity Read ↗

PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatmentSemantic proximity Read ↗

Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future OpportunitiesSemantic proximity Read ↗

PARP Inhibitors and Haematological Malignancies—Friend or Foe?Semantic proximity Read ↗

Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity Read ↗

Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.Semantic proximity Read ↗

Hematologic complications in patients exposed to PARP inhibitorsSemantic proximity Read ↗

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.